ArticleBMC gastroenterology2025
Circular RNA profiling and functional analysis implicate circ-ANKRD36C as a potential prognostic biomarker in gastric cancer.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Circular RNA circAHSA1 serves as a stable serum biomarker for the diagnosis and progression of gastric cancer.Translational oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundGastric cancer (GC) remains one of the leading causes of cancer-related mortality worldwide due to its aggressive nature and high metastatic potential. Circular RNAs (circRNAs), characterized by covalently closed loop structures and high molecular stability, have emerged as important regulatory molecules in cancer biology. However, the biological functions and molecular mechanisms of most circRNAs in GC remain largely unexplored.
methodsWe conducted circRNA microarray profiling on three pairs of primary GC tissues and matched adjacent normal tissues to identify differentially expressed circRNAs. The expression of circ-ANKRD36C was validated by quantitative reverse transcription polymerase chain reaction (qRT-PCR) in additional clinical specimens. Functional assays were performed to assess the effects of circ-ANKRD36C knockdown on GC cell proliferation, migration, and invasion. Dual-luciferase reporter assays provided evidence of direct interaction between circ-ANKRD36C and miR-15a-5p. Clinicopathological correlations and survival outcomes were analyzed in 84 paired GC and normal tissue samples.
resultsCirc-ANKRD36C was significantly upregulated in GC tissues. Knockdown of circ-ANKRD36C suppressed GC cell proliferation, migration, and invasion in vitro. Dual-luciferase assays supported its direct interaction with miR-15a-5p, potentially influencing oncogenic targets such as BMI1 and CCND1. Clinically, high circ-ANKRD36C expression was associated with shorter overall survival (OS). Multivariate Cox regression analysis suggested its independent prognostic value (hazard ratio [HR] = 2.41; 95% confidence interval [CI] = 1.22–4.77; P = 0.011).
conclusionCirc-ANKRD36C is upregulated in gastric cancer and may serve as a prognostic biomarker. Functional evidence suggests it could act as a candidate regulator, but its mechanistic role requires further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.